Natco Pharma Q1 FY27 Results: Revenue Rs 735 Cr, PAT Rs 122 Cr
- August 18, 2026
- Posted by: Ankit Jaiswal
- Category: Market
Natco Pharma Q1 FY27: Revenue Rs 735 Cr (-44% YoY). PAT Rs 122 Cr (-74% YoY). Gross Profit Rs 139 Cr. Consolidated. CMP Rs 889.95 on Aug 14, 2026.
Quick Answer
Natco Pharma Q1 FY27 results showed consolidated revenue of Rs 735 crore (-44% YoY) with pat of Rs 122 crore (-74% YoY) and gross profit of Rs 139 crore. Results announced on August 14, 2026.
Natco Pharma Q1 FY27 results showed consolidated revenue at Rs 735 crore, compared to Rs 1329 crore in Q1 FY26 — a -44% change. The company operates across its core business segments and reported these Q1 FY27 results on August 14, 2026.
The Natco Pharma Q1 FY27 results showed gross profit of Rs 139 crore (-72% YoY) versus Rs 513 crore in Q1 FY26. The pat of Rs 122 crore (-74% YoY) versus Rs 480 crore reflects the overall operating and financial outcome for the quarter.
Click Here – Get Free Investment Predictions
Natco Pharma Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Crore) | Q1 FY26 (Rs Crore) | YoY Change |
|---|---|---|---|
| Revenue | 735 | 1329 | -44% |
| Gross Profit | 139 | 513 | -72% |
| PAT / PAT | 122 | 480 | -74% |
Natco Pharma Q1 FY27 Performance Analysis
Use the Univest Screener to track Natco Pharma live financials and Q1 FY27 results
Natco Pharma Q1 FY27 results showed revenue of Rs 735 crore (-44% YoY), reflecting the prevailing market conditions and the company’s operational execution across its primary business segments.
Gross Profit at Rs 139 crore (-72% YoY) in Natco Pharma Q1 FY27 results captures the direct cost economics — input costs, manufacturing or service delivery expenses — relative to the revenue generated in Q1 FY27.
The pat of Rs 122 crore (-74% YoY) in Natco Pharma Q1 FY27 results represents the bottom-line outcome after accounting for all operating expenses, other income, and below-gross-profit costs.
Investors should evaluate Natco Pharma Q1 FY27 results in the context of industry growth rates, the company’s competitive position, cost structure, and management’s FY27 guidance to form a comprehensive investment view.
Key Business Factors in Q1 FY27
Revenue Performance
Natco Pharma Q1 FY27 results show revenue of Rs 735 crore (-44% YoY). Revenue trend reflects sector demand dynamics, competitive intensity, and the company’s market positioning in Q1 FY27.
Margin and Cost Dynamics
Gross Profit of Rs 139 crore (-72% YoY) in Natco Pharma Q1 FY27 results reflects input cost trends, pricing power, and operational efficiency in the quarter.
PAT Outcome
The pat of Rs 122 crore (-74% YoY) captures the overall financial performance including both operational results and non-operating income or charges in Q1 FY27 results.
Dividend Details
Natco Pharma has not declared a dividend for Q1 FY27. Annual dividend consideration will depend on full-year FY27 performance.
FY27 Outlook
The FY27 outlook for Natco Pharma will be shaped by the revenue and margin trajectory visible from Q1 FY27 results. Key factors include sector demand trends, input cost management, competitive dynamics, and management’s execution capability.
Investors should monitor Q2 FY27 results for confirmation of the trends observed in Natco Pharma Q1 FY27 results, particularly regarding revenue growth sustainability and margin progression.
Natco Pharma Stock Performance
Download the Univest iOS App or Univest Android App to track Natco Pharma share price live and stay updated on quarterly results.
Natco Pharma shares traded at Rs 889.95 on August 14, 2026. The stock’s movement reflects the market’s immediate assessment of Q1 FY27 results in the context of prevailing sector valuations and growth expectations.
Key Risks
Revenue Growth Sustainability
Maintaining or improving the revenue trajectory from Natco Pharma Q1 FY27 results depends on sector demand, competitive dynamics, and successful business development initiatives.
Margin Management
Gross and net margin sustainability in Natco Pharma Q1 FY27 results and subsequent quarters is subject to input cost trends, pricing competition, and operational efficiency.
Macro and Sector Risks
Broader macroeconomic conditions, interest rate trends, and sector-specific regulatory changes could impact Natco Pharma’s earnings trajectory from Q1 FY27 results.
Conclusion
Natco Pharma Q1 FY27 results show revenue of Rs 735 crore (-44% YoY) and pat of Rs 122 crore (-74% YoY) — reflecting the company’s operating performance for April to June 2026.
Investors should conduct detailed sector and company-specific analysis, assess management strategy and guidance, before making investment decisions. Consult a SEBI-registered financial advisor.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Natco Pharma Q1 FY27 Results
When were Natco Pharma Q1 FY27 results announced?
Ans. Natco Pharma Q1 FY27 results were announced on August 14, 2026, covering the April to June 2026 quarter on a consolidated basis.
What was Natco Pharma’s revenue in Q1 FY27?
Ans. Natco Pharma reported consolidated revenue of Rs 735 crore in Q1 FY27, -44% from Rs 1329 crore in Q1 FY26.
What was Natco Pharma’s pat in Q1 FY27?
Ans. Natco Pharma’s pat was Rs 122 crore in Q1 FY27, -74% from Rs 480 crore in Q1 FY26.
What drove Natco Pharma’s Q1 FY27 performance?
Ans. Natco Pharma Q1 FY27 results reflect the company’s sector positioning, operational execution, cost management, and prevailing market conditions in April-June 2026.
Did Natco Pharma declare a dividend for Q1 FY27?
Ans. No dividend has been declared for Q1 FY27. Annual dividend prospects will depend on full-year FY27 earnings performance.
What is the outlook for Natco Pharma after Q1 FY27 results?
Ans. The FY27 outlook depends on revenue and margin sustainability from Q1 FY27 results, sector demand trends, and management guidance for the rest of FY27.
Is Natco Pharma a good investment after Q1 FY27 results?
Ans. Natco Pharma Q1 FY27 results provide the latest financial update. Investors should assess sector positioning, valuation, and growth prospects before investing. Consult a SEBI-registered advisor.
